LongevitAI 🧬 AI + Longevity

A city where you can test longevity therapies banned almost everywhere else already exists. That city is Prospera. The new film “Once in Prospera” shows something much bigger than just another biotech startup story: a place built for regulatory arbitrage — where people try to move science faster by moving it outside normal legal systems. Why it matters: 🟢 Prospera lets residents create alternative regulatory frameworks 🟢 taxes can be paid in Bitcoin 🟢 companies can run experiments that would be nearly impossible in most countries 🟢 Unlimited Bio is using that environment to develop combinatorial life-extension therapies That’s the real story. Not “crazy longevity people in a weird city.” But this: biotech is starting to migrate to jurisdictions that compete on permission. If traditional states move too slowly, capital and experiments don’t just wait. They relocate. That creates a serious new question: will the future of medicine be decided in major hospitals and FDA-style systems — or in semi-autonomous zones built specifically to bypass them? 🗒 Prospera is not just a place. It’s a preview. When regulation becomes a product, the next frontier of biotech may be shaped less by discovery — and more by where the rules are weakest.

Google may not be losing the AI race — it may be refusing to play the same game. That’s the real thesis. While OpenAI and Anthropic keep pushing the classic bet — bigger models, more chips, more data, more scaling — Google seems to be running a two-front strategy. Front one: 🟢 keep Gemini competitive enough to defend Search, Workspace, and Cloud Front two: 🟢 invest in whatever comes after transformers if pure scaling starts to plateau That second front is the interesting one. Instead of betting everything on one giant monolithic LLM, Google is spreading chips across: • world models • embodied agents / robotics • alternative intelligence architectures • DeepMind’s scientific AI stack • longer-horizon bets like Project Pi The logic is brutal and simple: if scaling laws keep working, Google survives with Gemini. If scaling laws hit a wall, Google may be one of the few labs already building the escape routes. That’s why Google can look “behind” in the benchmark war while still being strategically dangerous. OpenAI and Anthropic are optimizing for: • the next model release • the next coding agent leap • the next product cycle Google may be optimizing for: • the next paradigm 🗒 The market reads Google as slow because it’s comparing quarterly products. But the smarter read may be this: Google is not trying to win the current LLM race cleanly — it’s trying to still be alive, and maybe dominant, after the current race stops mattering.

MIT is pushing a radical idea: the brain may work less like a computer and more like a wave machine. That’s the core of the new theory. For decades, the dominant metaphor was simple: neurons fire, synapses store information, the brain computes like a biological network. MIT’s argument is sharper: thought, action, and even consciousness may emerge from analog computations performed by traveling electrical waves across the cortex. In other words, brain waves may not be a side effect. They may be the actual computational mechanism. Why this matters: 🟢 synapses can store memory and knowledge 🟢 but storage alone does not explain how the brain pulls the right thing out in milliseconds 🟢 wave dynamics may be the missing layer that organizes and mobilizes that information in real time The consciousness angle is even bigger. According to the theory, consciousness appears when these waves create a globally integrated state across the cortex. One clue: different anesthetics with very different molecular actions all seem to break the same large-scale wave dynamics — and consciousness disappears. That suggests the common denominator may not be chemistry itself. It may be the collapse of the brain’s wave-based coordination. 🗒 The brain is not just running code on wet hardware. It is using its own physics as the computation. And if you want to track how your body is aging while science figures out the brain, try AgePilot bot.

By adulthood, it may already be too late to win aging just by slowing new glycation. That’s the uncomfortable point. Advanced glycation end products (AGEs) build up when sugars react with proteins, lipids, and other molecules. Over time they stiffen tissues, damage blood vessels, worsen inflammation, and contribute to aging. The problem is timing. By the time you’re a fully grown adult, a big part of the damage may already be: 🟢 accumulated 🟢 crosslinked into long-lived tissues 🟢 hard to reverse just by blocking new formation That’s why “anti-glycation” is often oversold. Stopping some new AGEs from forming is useful in theory. But if old crosslinks are already sitting in: • arteries • skin • connective tissue • kidneys • the extracellular matrix …then slowing the next layer of damage may not be enough. The real challenge is bigger: not just preventing new glycation, but dealing with the glycation that is already there. That means the field probably needs more than: 🟠 supplements with weak anti-glycation claims 🟠 blood sugar hand-waving 🟠 generic antioxidant marketing It needs therapies that either: • remove damaged structures • break harmful crosslinks • or replace the tissues carrying the damage 🗒 The harsh truth is that aging is often easier to prevent early than to unwind later. If you want to track where your biology may already be drifting, try AgePilot bot: https://t.me/AgePilotBot?start=ref_134163805

Higher education may be one of the strongest longevity factors humans have. Women now outnumber men in higher education globally: 112 per 100. In 1970, the ratio was just 59 women per 100 men. So this didn’t just equalize. It reversed. And that matters far beyond careers. Because higher education is one of the strongest predictors of longer life. More education is consistently linked to: • lower mortality • better health literacy • higher income • healthier behavior • lower smoking rates • better access to care • longer lifespan So this is not just a culture story. It’s also a longevity story. In many countries, women are now building an advantage not only in diplomas, but potentially in: • health outcomes • resilience • future lifespan Meanwhile, in richer countries, fewer men in university is becoming a real structural problem: if men fall behind in education, they often fall behind in longevity too. The map still shows two worlds: • in poorer countries, fewer women in university often means barriers to access • in richer countries, fewer men in university increasingly means male underperformance in the education pipeline The long-term implication is brutal: if education is one of the strongest longevity multipliers, then the gender gap in education may become a gender gap in healthy lifespan too. 🧬 And if you want facts instead of guesswork, you can check your sex through a DNA test — and unlock 1000+ parameters about your body. Use my link for complete DNA sequencing

Drinking water during meals does not “ruin digestion” — and soup may actually help you eat less. The old myth says water dilutes stomach acid and makes digestion worse. That sounds smart. It’s mostly nonsense. In one study, 200 ml of water raised stomach pH above 4 in most people — but only for about 3 minutes. Then the stomach corrected it. So yes, water briefly dilutes acid. No, it does not meaningfully break digestion. That also helps explain a funny effect: some people feel relief from heartburn immediately after taking omeprazole, even though the drug itself cannot work that fast. Part of the instant relief may just be the glass of water. The more useful finding is about appetite. Studies comparing meals with: • water • diet cola • regular cola • juice • milk found that non-caloric drinks did not increase food intake, while caloric drinks simply added extra calories on top. Translation: if you’re trying to lose fat, drinking calories is stupid. Water also seems to help with weight loss directly. In a 12-week randomized study, older adults on a low-calorie diet who drank 500 ml of water before meals lost about 2 kg more than the diet-only group. Soup is even better. Large population data and feeding studies suggest that soup is associated with: 🟢 lower body weight 🟢 lower obesity risk 🟢 better satiety 🟢 lower calorie intake at the meal One simple effect matters most: a bowl of soup before the main course can reduce total meal calories by about 20%. That’s huge for something this boring. The trick is obvious: • broth-based or light soups work best • if your “soup” is basically liquid cream and fat, congratulations, you invented a second main course So the real rule is simple: Water during meals is fine. Water before meals can help weight loss. Soup is not sacred — it’s just an effective anti-overeating tool. 🧬 And if you want facts instead of guesswork, you can check your sex through a DNA test — and unlock 1000+ parameters about your body. U

Semaglutide extended lifespan in old mice by 12.4% — but the real question is whether it slows aging or just fixes metabolic drift. That’s the part worth arguing about. In a new Nature study, researchers gave semaglutide to 20-month-old female mice that were already old — not diabetic, not massively obese, just aging. Median lifespan went from 742 to 834 days. That’s a real signal. But there’s an immediate problem: the mice on semaglutide also ate about 24% less. So what actually extended life? • the drug itself • or plain old calorie restriction That distinction matters. Because on some outcomes, semaglutide looked a lot like calorie restriction: • physical activity • coordination • muscle function • endurance But on others, it may have done better: 🟢 spatial memory 🟢 exploratory behavior 🟢 glucose control 🟢 signs of neurogenesis in the hippocampus It also appeared to push several aging-related systems in a younger direction: • less inflammation • less cellular senescence • less DNA damage • better mitochondrial status • better proteostasis • a partial reversal of the age-related myeloid shift in blood stem cells That’s why this is more interesting than another obesity headline. The real possibility is that semaglutide may be acting not just as a weight-loss drug, but as a partial corrector of age-related metabolic and inflammatory drift. Still, don’t oversell it. Important caveats: 🟠 this was in mice 🟠 only females were tested 🟠 the lifespan gain was not fully disentangled from calorie restriction 🟠 834 days is not some impossible lifespan for this strain So no, this is not proof that Ozempic is a longevity drug. But it is one of the strongest hints yet that GLP-1 drugs may affect more than body weight — potentially touching the biology of aging itself. 🧬 The future of longevity will belong to people who measure their biology instead of guessing. Use my link for complete DNA sequencing and unlock 1000+ parameters about your body: https://shop.t

The second of the seven has a name. Navier–Stokes. For a century the equation of flowing water refused to say whether it always stays smooth, or whether it can tear itself open. In 2003 Grigori Perelman closed the Poincaré conjecture. The first of seven. He declined the million, and the room. Today OpenAI claims the second. Not the Astra in your browser. A model they called significantly more capable than GPT-6 Astra. A thousand agents on the Euler cousin. Ten thousand on the full problem. 88 hours. About $15 million if you asked to run the same search. They say no human opened the working trace. The Clay Institute has not stamped it. A day earlier, Buckmaster and Alpöge published the stepping-stones, and a fight over credit had already begun. The coronation is announced. The priests have not nodded. Still. Two of seven. The first took a man who walked away. The second, if it holds, was a machine that did not look up. https://x.com/OpenAI/status/2097374640582668336

An AI-designed drug just made six independent aging clocks move younger — in humans. Not a mouse study. Not another rapamycin remix. Rentosertib (Insilico): generative-AI TNIK inhibitor, aging biology in the brief from day one. Phase IIa IPF trial. Serum proteomics. Six clocks (ProtAge, OrganAge, PAC + more). All six: lower predicted biological age vs placebo. Peak: ~3–4 years younger at week 4 on 30 mg BID (up to ~6 on one clock). Why this matters: 🟣 AI found the target 🟣 AI designed the molecule 🟣 aging clocks in the trial design, not bolted on later 🟣 best age-clock dose ≠ best lung dose — not just "lungs improved" Caveats: 🟠 n=42 proteomic subset 🟠 every patient had IPF 🟠 clocks ≠ proof you slowed aging 🟠 healthy-volunteer data still missing 🗒 Real shift: disease trials can hunt geroprotection in parallel — years earlier than post-approval leftovers. Baseline while science catches up → AgePilot Source: Nature Biotechnology (Zhavoronkov et al., Sept 2026)